10-K: Marker Therapeutics Reports 2024 Results, Highlights Progress in Lymphoma and Pancreatic Cancer Trials

Marker Therapeutics' 2024 10-K filing details the company's financial status, clinical trial progress, and strategic shifts, including focusing on MT-601 for lymphoma and pancreatic cancer and MT-401-OTS for AML and MDS.

Summary

• Marker Therapeutics, a clinical-stage immuno-oncology company, specializes in developing T cell-based immunotherapies.
• The company's lead product candidate, MT-601, is being evaluated in a Phase 1 study (APOLLO) for relapsed or refractory lymphoma patients who have failed or are ineligible for anti-CD19 CAR-T cell therapy.
• Interim data from the APOLLO study showed objective responses in 78% of patients at first assessment, with 44.4% demonstrating complete response.
• MT-601 is also being investigated for pancreatic cancer, with a $9.5 million grant from CPRIT and a $2 million grant from the NIH SBIR program supporting the clinical investigation.
• The company discontinued the Phase 2 ARTEMIS study of MT-401 to prioritize the MT-401-OTS program for AML and MDS patients.
• Marker Therapeutics reported a net loss from continuing operations of $10.7 million for the year ended December 31, 2024.
• The company anticipates being able to fund operating expenses and capital expenditure requirements into the first quarter of 2026, assuming no additional grant funds are received.
• The company plans to raise additional capital through the issuance of common shares and receipt of additional grant funds, which could enable it to fund operating expenses and capital expenditure requirements beyond the first quarter of 2026.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive clinical trial results and grant funding, the company's financial situation and reliance on external factors create uncertainty.

Positives

• MT-601 demonstrates promising early objective responses in lymphoma patients who have failed or are ineligible for anti-CD19 CAR-T cell therapy.
• The company has secured significant grant funding to support the clinical development of MT-601 in pancreatic cancer.
• The MT-401-OTS program has the potential to provide treatment to patients in as little as 72 hours.
• The company has established a cellular inventory manufactured from healthy donors for the MT-401-OTS program.
• The company has an exclusive license agreement with Baylor College of Medicine for MAR-T cell therapy technology.

Negatives

• The company has a history of operating losses and expects losses to continue for the indefinite future.
• The company has not generated any revenue from the sales of products and has not yet demonstrated ability to obtain regulatory approval, formulate and manufacture commercial-scale products, or conduct sales and marketing activities necessary for successful product commercialization.
• The company is dependent on third-party vendors to maintain and support its manufacturing and cell processing.
• The company is reliant upon specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all.
• The company may not be able to establish or maintain the third-party relationships, including strategic collaborations, that are necessary to develop, commercialize and/or market some or all of our product candidates.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt.
• The company's product candidates are in clinical development and may not receive regulatory approval or be successfully commercialized.
• The FDA regulatory approval process is lengthy and time-consuming, and the company may experience significant delays.
• The results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.
• The company is dependent on third-party vendors to maintain and support its manufacturing and cell processing.
• The company's commercial success depends upon attaining significant market acceptance of its product candidates, if approved.
• The biotechnology and immunotherapy industries are characterized by rapid technological developments and a high degree of competition.
• The company is subject to extensive regulation, which can be costly, time consuming and can subject us to unanticipated delays.
• The price of the company's stock may be volatile.

Future Outlook

Marker Therapeutics anticipates being able to fund its operating expenses and capital expenditure requirements into the first quarter of 2026, assuming no additional grant funds are received, and plans to raise additional capital through the issuance of common shares and receipt of additional grant funds to extend this runway.

Management Comments

• Study participants showed early objective responses with and without lymphodepletion.
• Immunomonitoring data confirmed that lymphodepletion enhanced the expansion and persistence of MAR-T cell clones in vivo.

Industry Context

The document highlights the competitive landscape in the treatment of relapsed lymphoma, noting the limitations of existing CD19-directed CAR-T cell therapies and the need for alternative treatments. Marker Therapeutics positions MT-601 as a potential solution for patients who relapse after CAR-T therapy, emphasizing its multi-antigen targeting approach and favorable safety profile.

Comparison to Industry Standards

• The document compares Marker's MAR-T cell therapy to CAR-T cell therapies, highlighting potential advantages such as multiple targets, clinical safety, and non-genetically engineered T cell products.
• The document references published CD19 CAR-T studies that have been associated with substantial tolerability concerns, including a Phase 1 trial in which 95% of patients had Grade 3 or higher adverse events during treatment and current investigations by the FDA regarding the risk of CAR-T cell therapies to potentially induce secondary cancers.
• The document compares favorably with HSCT outcomes for risk-matched AML/MDS patients post-HSCT [median LFS of nine to 15 months and two-year survival probability of 42%].

Related Party Transactions

• The company has related party transactions with Cell Ready, LLC, and Baylor College of Medicine.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings.
• Employees: Potential for job security based on company performance and funding.
• Patients: Potential for new treatment options for lymphoma, pancreatic cancer, AML, and MDS.
• Suppliers: Continued business relationships for manufacturing and clinical trial support.

Next Steps

• Continue clinical development of MT-601 in lymphoma and pancreatic cancer.
• Advance the MT-401-OTS program in AML and MDS.
• Evaluate and qualify additional potential third-party manufacturing partners.
• Initiate a larger pivotal trial for Lymphoma in 2026.

Key Dates

Keywords

MAR-T cell therapy, immuno-oncology, lymphoma, pancreatic cancer, AML, MDS, clinical trials, MT-601, MT-401-OTS, regulatory approval